Skip to main content

Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease

Drugs volume 75, pages 1797–1806 (2015)Cite this article

Abstract

Tolvaptan (Jinarc®) is a highly selective vasopressin V2 receptor antagonist indicated for use in patients with autosomal dominant polycystic kidney disease (ADPKD). Tolvaptan is the first pharmaceutical agent to be approved in Europe for delaying the progression of ADPKD in adults with stage 1–3 chronic kidney disease at initiation of treatment. In the large phase III TEMPO 3:4 trial in adults with ADPKD, 3 years’ treatment with oral tolvaptan significantly reduced growth in total kidney volume and slowed renal function decline relative to placebo. Tolvaptan was also associated with a significantly lower rate of events for the composite secondary endpoint of time to investigator-assessed clinical progression relative to placebo, an effect that was largely attributable to reductions in the risk of worsening renal function and the risk of worsening kidney pain. Many of the most common adverse events in the tolvaptan group were related to its aquaretic mechanism of action (e.g. polyuria, nocturia, polydipsia and thirst). Tolvaptan was also associated with idiosyncratic elevations of liver enzymes which were reversible on discontinuation of the drug. Although the use of tolvaptan requires careful consideration and balancing of benefits and risks, current evidence suggests that tolvaptan is a promising new treatment option for patients with ADPKD.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 49.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287–301.

    Article  PubMed  Google Scholar 

  2. Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 2015;88(1):17–27.

    Article  PubMed  Google Scholar 

  3. McGovern AP, Jones S, van Vlymen J, et al. Identification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study. BMC Nephrol. 2014;15:182.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Neumann HP, Jilg C, Bacher J, et al. Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany. Nephrol Dial Transplant. 2013;28(6):1472–87.

    Article  CAS  PubMed  Google Scholar 

  5. Ars E, Bernis C, Fraga G, et al. Spanish guidelines for the management of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2014;29(Suppl 4):iv95–105.

    Article  PubMed  Google Scholar 

  6. Cornec-Le Gall E, Audrezet MP, Chen JM, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol. 2013;24(6):1006–13.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Wuthrich RP, Mei C. Pharmacological management of polycystic kidney disease. Expert Opin Pharmacother. 2014;15(8):1085–95.

    Article  PubMed  Google Scholar 

  8. European Medicines Agency. Tolvaptan (Samsca): summary of product characteristics. http://www.ema.europa.eu. Accessed 18 Sep 2015.

  9. Reif GA, Yamaguchi T, Nivens E, et al. Tolvaptan inhibits ERK-dependent cell proliferation, Cl(−) secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol. 2011;301(5):F1005–13.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Meijer E, Gansevoort RT, de Jong PE, et al. Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug. Nephrol Dial Transplant. 2011;26(8):2445–53.

    Article  CAS  PubMed  Google Scholar 

  11. European Medicines Agency. Tolvaptan (Jinarc): summary of product characteristics. 2015. http://www.ema.europa.eu. Accessed 18 Sep 2015.

  12. Aihara M, Fujiki H, Mizuguchi H, et al. Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury. J Pharmacol Exp Ther. 2014;349(2):258–67.

    Article  PubMed  Google Scholar 

  13. Shoaf SE, Wang Z, Bricmont P, et al. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects. J Clin Pharmacol. 2007;47(12):1498–507.

    Article  CAS  PubMed  Google Scholar 

  14. European Medicines Agency. Jinarc assessment report. 2015. http://www.ema.europa.eu. Accessed 18 Sep 2015.

  15. Torres VE, Meijer E, Bae KT, et al. Rationale and design of the TEMPO (tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3–4 study. Am J Kidney Dis. 2011;57(5):692–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Higashihara E, Torres VE, Chapman AB, et al. Tolvaptan in autosomal dominant polycystic kidney disease: three years’ experience. Clin J Am Soc Nephrol. 2011;6(10):2499–507.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Irazabal MV, Torres VE, Hogan MC, et al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2011;80(3):295–301.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Boertien WE, Meijer E, de Jong PE, et al. Short-term effects of tolvaptan in individuals with autosomal dominant polycystic kidney disease at various levels of kidney function. Am J Kidney Dis. 2015;65(6):833–41.

    Article  CAS  PubMed  Google Scholar 

  19. Boertien WE, Meijer E, de Jong PE, et al. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease. Kidney Int. 2013;84(6):1278–86.

    Article  CAS  PubMed  Google Scholar 

  20. Shoaf SE, Bramer SL, Bricmont P, et al. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide. J Cardiovasc Pharmacol. 2007;50(2):213–22.

    Article  CAS  PubMed  Google Scholar 

  21. Shoaf SE, Bricmont P, Mallikaarjun S. Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function. Kidney Int. 2014;85(4):953–61.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Shoaf SE, Kim SR, Bricmont P, et al. Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects. Eur J Clin Pharmacol. 2012;68(12):1595–603.

    Article  CAS  PubMed  Google Scholar 

  23. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407–18.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Torres VE, Devuyst O, Chapman AB, et al. Effect of tolvaptan in ADPKD by CKD stage: results from the TEMPO 3:4 trial [abstract plus poster]. In: World Congress of Nephrology; 2015.

  25. Muto S, Kawano H, Higashihara E, et al. The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial. Clin Exp Nephrol. 2015. doi:10.1007/s10157-015-1086-2.

    Google Scholar 

  26. Devuyst O, Chapman AB, Boklage S, et al. Tolerability of aquaretic-related symptoms: results from the TEMPO 3:4 trial [abstract plus poster]. In: World Congress of Nephrology; 2015.

  27. Watkins PB, Lewis JH, Kaplowitz N, et al. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf. 2015. doi:10.1007/s40264-015-0327-3.

    PubMed  Google Scholar 

  28. Nagao S, Nishii K, Katsuyama M, et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol. 2006;17(8):2220–7.

    Article  CAS  PubMed  Google Scholar 

  29. Wang X, Wu Y, Ward CJ, et al. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol. 2008;19(1):102–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Torres VE, Wang X, Qian Q, et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med. 2004;10(4):363–4.

    Article  CAS  PubMed  Google Scholar 

  31. Ong AC, Devuyst O, Knebelmann B, et al. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet. 2015;385(9981):1993–2002.

    Article  PubMed  Google Scholar 

  32. Alam A, Dahl NK, Lipschutz JH, et al. Total kidney volume in autosomal dominant polycystic kidney disease: a biomarker of disease progression and therapeutic efficacy. Am J Kidney Dis. 2015. doi:10.1053/j.ajkd.2015.01.030.

    PubMed  Google Scholar 

  33. Bhutani H, Smith V, Rahbari-Oskoui F, et al. A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int. 2015;88(1):146–51.

    Article  CAS  PubMed  Google Scholar 

  34. Otsuka Pharmaceutical Development and Commercialization. Open-label tolvaptan study in subjects with ADPKD (TEMPO 4/4). 2014. http://www.clinicaltrials.gov/ct2/show/NCT01214421. Accessed 18 Sep 2015.

  35. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan-treatment of ADPKD confers persistent EGFR improvement: results from the TEMPO 4:4 extension trial [abstract no. SO016]. In: 51st European Renal Association–European Dialysis and Transplant Association (ERA–EDTA) Congress; 2014.

  36. Spital A. Tolvaptan in autosomal dominant polycystic kidney disease. N Engl J Med. 2013;368(13):1257.

    Article  PubMed  Google Scholar 

  37. Black P, Sutton R. Commentary on: Tolvaptan in patients with autosomal-dominant polycystic kidney disease. Urology. 2013;81(4):705–6.

    Article  PubMed  Google Scholar 

  38. Torres VE, Gansevoort RT, Czerwiec FS. Tolvaptan in autosomal dominant polycystic kidney disease. N Engl J Med. 2013;368(13):1259.

    CAS  PubMed  Google Scholar 

  39. National Institute for Health and Care Excellence. Final appraisal determination document—tolvaptan for treating autosomal dominant polycystic kidney disease. 2015. http://www.nice.org.uk. Accessed 18 Sep 2015.

  40. Robinson P, McEwan P, Ong ACM, et al. Assessing the long term outcomes of autosomal dominant polycystic kidney disease (ADPKD) using the ADPKD outcomes model: a UK case study [abstract no. FP064 plus poster]. In: 52nd European Renal Association–European Dialysis and Transplant Association (ERA–EDTA) Congress. 2015.

  41. O’Reilly K, McEwan P, Bennett Wilton H, et al. Exploring the impact of tolvaptan on the long term rate of renal function decline using the ADPKD outcomes model [abstract no. FP055 plus poster]. In: 52nd European Renal Association–European Dialysis and Transplant Association (ERA–EDTA) Congress. 2015.

  42. Blanchette CM, Matter S, Chawla A, et al. Burden of autosomal dominant polycystic kidney disease: systemic literature review. Am J Pharm Benefits. 2015;7(2):e27–36.

    Google Scholar 

  43. Otsuka Pharmaceutical Development and Commercialization. Efficacy and safety of tolvaptan in subjects with chronic kidney disease between late stage 2 to early stage 4 due to autosomal dominant polycystic kidney disease. 2014. http://www.clinicaltrials.gov/ct2/show/NCT02160145. Accessed 18 Sep 2015.

  44. Otsuka Pharmaceutical Development and Commercialization. Open-label trial to evaluate the long term safety of titrated immediate-release tolvaptan in subjects with autosomal dominant polycystic kidney disease. 2014. http://www.clinicaltrials.gov/ct2/show/NCT02251275. Accessed 18 Sep 2015.

Download references

Acknowledgments

During the peer review process, the manufacturer of tolvaptan was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Hannah A. Blair & Gillian M. Keating

Authors
  1. Hannah A. Blair
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hannah A. Blair.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

Hannah Blair and Gillian Keating are salaried employees of Adis/Springer, are responsible for the article content and declare no relevant conflicts of interest.

Additional information

The manuscript was reviewed by: D. O’Donoghue, Salford Royal NHS Foundation Trust, Salford, UK; R. Torra, Inherited Kidney Diseases, Nephrology Department, Fundacio Puigvert, Barcelona, Spain; C. Willey, College of Pharmacy, University of Rhode Island, Kingston, RI, USA.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Blair, H.A., Keating, G.M. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease. Drugs 75, 1797–1806 (2015). https://doi.org/10.1007/s40265-015-0475-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-015-0475-x

Keywords

  • Autosomal Dominant Polycystic Kidney Disease
  • Tolvaptan
  • Urine Osmolality
  • Free Water Clearance
  • Total Kidney Volume